Phase 1 Start

CGEM: Phase1_Start: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia

October 15, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 15, 2026
Company: Cullinan Therapeutics, Inc. (CGEM)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 1 Start

Phase1_Start: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia

October 15, 2026

CGEM overview →

Company: Cullinan Therapeutics, Inc. (CGEM)

Other upcoming events for CGEM

Phase 2 StartPhase2_Start: A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

PDUFA DatePDUFA: 0001193125-26-411011